Impact MRSA -PCR on Patient Management

MRSA Bacteremia Clinical Trial

Official title:

Impact MRSA -PCR on Patient Management

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03096405
• Other study ID #: PCR-SARM
• Status: Completed
• Phase: N/A
• First received: March 25, 2017
• Last updated: May 24, 2017
• Start date: February 1, 2014
• Est. completion date: February 28, 2017

Study information

• Verified date: March 2017
• Source: Groupe Hospitalier Paris Saint Joseph
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Staphylococcus aureus represents one of the most met germs, with Escherichia coli, during bacteremia. Microbiologist distinguish at aureus S. two profiles of resistance in beta-lactamines: S. aureus sensitive to the methicillin ( SASM) and the S. aureus resistant to the methicillin ( SARM).

With the implementation of the MALDI-TOF, it is now possible to identify the origin responsible of the bacteremia the day of the positivity of the hemoculture ( J0) and to set up a treatment with adapted antibiotic, which, in the case of a sepsis to aureus S., is the vancomycine. Ye it was demonstrated, that the use of the vancomycine on the SASM increased the average duration of stay and a more important rate of relapse.

The PCR SARM was organized in the GHPSJ in 2014. It allows from the day of the positivity of the hemoculture ( J0), to determine the phenotype of resistance of S. aureus.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 50
• Est. completion date: February 28, 2017
• Est. primary completion date: March 31, 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Hemoculture positive to Staphylococcus Aureus Methicillin Sensitive

Exclusion Criteria:

• Positive test to Staphylococcus Aureus Methicillin Sensitive but not hospitalized.

Related Conditions & MeSH terms

• Bacteremia
• MRSA Bacteremia

Intervention

Diagnostic Test:
• Polymerase Chain Reaction of Methicillin Resistant Staphyloccus Aureus
Polymerase Chain Reaction of Methicillin Resistant Staphyloccus Aureus

Locations

Country	Name	City	State
France	Groupe Hospitalier Paris Saint Joseph	Paris	Ile-de-France

Sponsors (1)

Lead Sponsor	Collaborator
Groupe Hospitalier Paris Saint Joseph

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Adaptation duration of antibiotherapy		24 hours
Secondary	Mortality		Day 30
Secondary	average duration of hospitalization		day 30